Notícias

MNST trades above its 50- and 200-day SMAs as energy-drink growth, innovation and global momentum offset rising cost pressures.

Kraft Heinz beat Q2 earnings and sales estimates and raised its 2026 organic sales outlook, but weak North America volumes and margin pressure remain.

Kraft Heinz trades at a discount and generates strong cash flow, but weak volumes, inflation and softer earnings keep execution risk in focus.

Has the market finally become too pessimistic about Netflix, or has the sell-off created a place to jump in?

Tesla just hiked Cybertruck prices on a vehicle that has been called the biggest flop in automotive history, and the reasoning behind that decision is nearly impossible to defend.

These five software stocks turned the "AI kills SaaS" panic into their biggest tailwinds — and Wall Street thinks there's more growth ahead.

The bond market is a mess, but what do all the recent developments mean?

Does SOUN's stronger growth outlook make it a better voice AI bet than cash-generating CRNC?

The stock looked sleepy and its latest revenue print was down, but a careful look at the company’s backlog revealed a substantial increase in order volume was developing just beneath the surface.

Nuclear stocks are surging while the broad market barely stirs, but the announcements driving the move tell a very different story than the price action suggests.

Applied Optoelectronics 800G revenues surge more than tenfold year over year as demand outpaces supply and capacity expansion targets further growth through mid-2027.

Both payment giants just hit record highs on the same day, which sounds like a reason to celebrate owning either one until you realize the two stocks tell very different stories about which investor actually wins from here.

Bitcoin briefly cracked $80,000 for the first time in months, sending crypto mining stocks surging well past the broader digital infrastructure pack, but not every miner is rallying for the same reason.

Shares of Generate Biomedicines Inc (NASDAQ:GENB) jumped more than 20% on Tuesday as investors positioned ahead of the expiration of the company's post-IPO lock-up period. The lock-up, which ends Wednesday, will free company insiders, early investors and major shareholders to sell shares...

IBM pays nearly 4x Microsoft's dividend yield, but MSFT wins on margins and upside. Only one will fit your investing style.

Over the last six months, Tandem Diabetes’s shares have sunk to $22.45, producing a disappointing 13.7% loss - a stark contrast to the S&P 500’s 10.5% gain. This might have investors contemplating their next move.

Warren Buffett almost never chases mega-cap tech, which makes Berkshire's massive new position in Alphabet one of the most surprising moves in years and a signal worth taking seriously before the rest of the market catches on.

Critical Metals is surging nearly 20% while its rare earth peers sit flat or slide lower, and no company announcement explains the gap. One unverified catalyst keeps surfacing in trader circles, and it has nothing to do with the ground under Greenland.

Apple just pulled back from its 52-week high while retail sentiment sours and analysts argue the valuation leaves no room for error. Here is why that pessimism may be the most reliable entry signal the stock has offered all year.

While Palantir’s latest results have not eliminated valuation and competition risks, they have provided stronger evidence its competitive position and demand remain robust.

Oracle has dropped nearly 40% over the past year, yet one investor keeps hitting the buy button while the crowd runs the other way. The reason comes down to a valuation gap hiding in plain sight inside the filings everyone else is reading.

Over the past six months, Lockheed Martin’s shares (currently trading at $564.17) have posted a disappointing 12.9% loss, well below the S&P 500’s 10.5% gain. This might have investors contemplating their next move.

Chipotle's focus on digital engagement, menu innovation and unit expansion bode well. Yet high costs pose concerns.

Adobe trades at $276.06 per share and has stayed right on track with the overall market, gaining 7.1% over the last six months. At the same time, the S&P 500 has returned 10.5%.

A Taiwanese indictment named individuals tied to Super Micro and NVIDIA, but whether the companies themselves face liability depends on a legal distinction that sent one stock soaring 8% while the broader tech tape went nowhere.

Intel is putting $20 billion behind its foundry ambitions as AI demand strengthens, though there are risks.

MPC offers a cheaper valuation and MPLX stability, but VLO's stronger balance sheet and momentum give it the edge in this refiner face-off.

Since February 2026, First Merchants has been in a holding pattern, posting a small return of 2% while floating around $41.94. The stock also fell short of the S&P 500’s 10.5% gain during that period.

Moderna just posted an 11% surge with zero news behind it, while its longtime mRNA peer BioNTech can barely keep pace with the broader biotech sector. Something broke between these two names, and figuring out what it means for your position is more urgent than it looks.

ABT edges DXCM on price-target upside and valuation, while both pursue CGM growth through innovation, adoption and strong liquidity.